The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...

July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

On Wednesday, the FDA approved Eli Lilly And Co’s (NYSE:LLY) Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn ...

A NEW method for detecting bowel cancer is more than 90 per cent accurate at predicting which higher risk people will develop ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.

The groundbreaking study, funded by Cancer Research UK, has shown more than 90% accuracy in predicting bowel cancer risk in ...

Michael Osso leads the Crohn's & Colitis Foundation as president and CEO. The Foundation, the world's largest public nonprofit dedicated to inflammatory bowel disease (IBD), aims to find cures and ...

Omvoh demonstrated 53% clinical remission and 46% endoscopic response in Crohn's patients after one year ... for moderately to severely active ulcerative colitis (UC) in adults.

Lilly has also submitted marketing applications for Mirikizumab-mrkz in Crohn’s disease around the globe, including in the ...